HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 293/4/E1085    most recent 00275.2007v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Johnson, K. M. S. Articles by Cherrington, A. D. Search for Related Content PubMed PubMed Citation Articles by Johnson, K. M. S. Articles by Cherrington, A. D.

Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels

Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee

Submitted 2 May 2007 ; accepted in final form 3 August 2007

After a meal, glucagon-like peptide-1 (GLP-1) levels in the hepatic portal vein are elevated and are twice those in peripheral blood. The aim of this study was to determine whether any of GLP-1's acute metabolic effects are initiated within the hepatic portal vein. Experiments consisted of a 40-min basal period, followed by a 240-min experimental period, during which conscious 42-h-fasted dogs received glucose intraportally (4 mg·kg^–1·min^–1) and peripherally (as needed) to maintain arterial plasma glucose levels at 160 mg/dl. In addition, saline was given intraportally (CON; n = 8) or GLP-1 (1 pmol·kg^–1·min^–1) was given into the hepatic portal vein (POR; n = 11) or the hepatic artery (HAT; n = 8). Portal vein plasma GLP-1 levels were basal in CON, 20x basal in POR, and 10x basal in HAT, whereas levels in the periphery and liver were the same in HAT and CON. The glucose infusion rate required to maintain hyperglycemia was significantly greater in POR (8.5 ± 0.7 mg·kg^–1·min^–1, final 2 h) than in either CON or HAT (6.0 ± 0.5 or 6.7 ± 1.0 mg·kg^–1·min^–1, respectively). There were no differences among groups in either arterial plasma insulin (24 ± 2, 23 ± 3, and 23 ± 3 µU/ml for CON, POR, and HAT, respectively) or glucagon (23 ± 2, 30 ± 3, and 25 ± 2 pg/ml) levels during the experimental period. The increased need for glucose infusion reflected greater nonhepatic as opposed to liver glucose uptake. GLP-1 infusion increased glucose disposal independently of changes in pancreatic hormone secretion but only when the peptide was delivered intraportally.

dog; liver; glucagon-like peptide-1; hepatic portal vein

This article has been cited by other articles:

				K. M. S. Johnson, D. S. Edgerton, T. Rodewald, M. Scott, B. Farmer, D. Neal, and A. D. Cherrington Intraportally delivered GLP-1, in the presence of hyperglycemia induced via peripheral glucose infusion, does not change whole body glucose utilization Am J Physiol Endocrinol Metab, February 1, 2008; 294(2): E380 - E384. [Abstract] [Full Text] [PDF]